common.study.topics.clinical

Randomized on-X Anticoagulation Trial

common.study.values.description

“Randomized On-X Anticoagulation Trial”

Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(CoumadinAR) or on antiplatelet drugs (aspirin/PlavixAR) only rather than the standard dose of Coumadin and aspirin presently recommended by ACC/AHA or ACCP professional societies.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Recruiting patients only common.study.methods.is-healthy-yes

Device - On-X valve using reduced anticoagulation

Valve replacement with antiplatelet agents or lowered warfarin

Device - On-X Valve with Standard warfarin Therapy

Valve replacement with standard dosage warfarin

participant.views.study.view.additional

participant.views.study.view.scientific-title

Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT)

common.study.values.clinical-trial-id

NCT00291525

participant.views.study.view.id

mepY2a